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Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma of B-cell
origin with frequent expression of functional B-cell receptors (BCRs). Here we report that
expression cloning followed by antigen screening identifies DNA-directed RNA polymerase
beta’ (RpoC) from Moraxella catarrhalis as frequent antigen of BCRs of IgD+ LP cells. Patients
show predominance of HLA-DRB1*04/07 and the IgVH genes encode extraordinarily long
CDR3s. High-titer, light-chain-restricted anti-RpoC IgG1/κ-type serum-antibodies are addi-
tionally found in these patients. RpoC and MID/hag, a superantigen co-expressed by Mor-
axella catarrhalis that is known to activate IgD+ B cells by binding to the Fc domain of IgD,
have additive activation effects on the BCR, the NF-κB pathway and the proliferation of IgD+
DEV cells expressing RpoC-specific BCRs. This suggests an additive antigenic and super-
antigenic stimulation of B cells with RpoC-specific IgD+ BCRs under conditions of a per-
missive MHC-II haplotype as a model of NLPHL lymphomagenesis, implying future treatment
strategies.
https://doi.org/10.1038/s41467-020-16375-6 OPEN
1 José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany. 2 Dr.
Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany. 3 Saarland University Medical School, Institute of Pathology, Homburg/
Saar, Germany. 4 Institute of Medical Microbiology and Hygiene, University of Saarland, Homburg, Germany. 5 German National Reference Center for
Clostridoides (Clostridium) difficile, Institute for Laboratory Medicine, Microbiology and Hygiene, Christophorus Kliniken, Coesfeld, Germany. 6 Institute of
Medical Microbiology and Infection Control, University Hospital of the Goethe University, Frankfurt am Main, Germany. 7 Institute of Cell Biology (Cancer
Research), University of Duisburg-Essen, Medical School, Essen, Germany. 8Deutsches Konsortium für translationale Krebsforschung (DKTK),
Heidelberg, Germany. 9 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology, and
Division of Rheumatology, University Hospital Frankfurt Goethe University, Frankfurt am Main, Germany. 10Department of Pathology, Tampere University
Hospital and University of Tampere, 33520 Tampere, Finland. 11 Department of Immunology, Genetics and Pathology, Uppsala University Hospital,
Uppsala, Sweden. 12 Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland. 13 University of Cologne, First Department of Internal
Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany. 14German Hodgkin Study Group, First Department of Internal
Medicine University Hospital Cologne, Cologne, Germany. 15 Frankfurt Institute of Advanced Studies, Frankfurt am Main, Frankfurt, Germany. 16These authors
contributed equally: Lorenz Thurner, Sylvia Hartmann. 17These authors jointly supervised this work: Martin-Leo Hansmann, Michael Pfreundschuh.
✉email: lorenz.thurner@uks.eu









Nodular lymphocyte-predominant Hodgkin lymphoma(NLPHL) accounts for 5–16% of all Hodgkin lymphoma(HL) cases1, and IgD+ NLPHL represents a distinct
clinical subtype, with a strong (>20:1) male predominance2. The
disease-defining lymphocyte predominant (LP) tumor cells
represent only a small proportion of the total tumor infiltrate
and are widely outnumbered by reactive cells. LP cells have a
late germinal-center B-cell phenotype and are closely related to
the tumor cells of T-cell/histiocyte-rich large B-cell lymphoma
(THRLBCL)3,4. LP cells harbor recurrent mutations in SGK1,
DUSP2, JUNB, and SOCS1, frequent translocations affecting the
B-cell lymphoma 6 (BCL6) gene, usually have a preserved B-cell
phenotype, and often express a functional B-cell receptor
(BCR)3,5–10. Intraclonal immunoglobulin variable (IgV) region
gene diversification7, the strong expression of BCL611, and
activation-induced cytidine deaminase (AID)12,13, and a histo-
logical picture that resembles germinal centers indicate an
ongoing immune response. Activation of the nuclear factor
(NF)-κB pathway is observed in LP cells3, but NF-κB activity in
LP cells is neither caused by mutations in NFKBIA or
TNFAIP314 nor by Epstein-Barr virus (EBV)15 infection and,
thus, could represent a consequence of chronic BCR stimulation.
Because IgD+ NLPHL has a predilection for cervical lymph
nodes, we addressed the question of whether bacteria in the
upper respiratory tract play a role in the pathogenesis of this
lymphoma. To identify the antigenic targets of BCRs expressed
on LP cells, recombinant antigen-binding fragments (Fabs) were
constructed and screened for their ability to bind with patho-
gens and auto-antigens.
Here we report that IgD+ LP cell-derived Fabs bind the
Moraxella catarrhalis antigen DNA-directed RNA polymerase
beta’ (RpoC) and thus reveal together with a permissive HLA
class II haplotype of the patients and presence of light-chain-
restricted serum antibodies a bacterial infection as trigger for the
lymphomagenesis of IgD+ NLPHL.
Results
Patients and Ig V gene characteristics. Functional Ig heavy and
light chain genes were successfully amplified from microdissected
LP cells from 12 of 22 NLPHL cases of a screening cohort from
Germany and Finland, including two composite lymphomas
consisting of an NLPHL part (case #7a and #8a) and a diffuse
large B cell lymphoma (DLBCL) part (case #7b and #8b) in the
same lymph node. In a validation cohort, composed of only IgD+
NLPHL cases from Switzerland and Sweden, the success rate was
3/5 (#13-#15). The median age of patients with successfully
amplified IgV genes was 30 years. Eight patients had IgD+ LP
cells (Supplementary Fig. 1), and five of these patients were
adolescents (Table 1). Two IgD+ NLPHL samples were obtained
from inguinal lymph nodes, but these were relapses. A male
predominance was observed among the NLPHL cases (13 of 15).
All cases had mutated IgV genes, with mutation frequencies for
heavy and light chain IgV genes (VH and VL, respectively) ran-
ging between 0% and 18.0% (average: 8.3% for VH and 4.8% for
VL gene segments; Table 2). The complementarity determining
region (CDR) 3 of VH region genes isolated from IgD+ LP cells
were significantly longer (median: 30 amino acids; mean: 29.95 ±
1.048 [SEM] amino acids; n= 8), compared with the CDR3 of VH
region genes isolated from IgD− LP cells (median: 17 amino
acids; mean: 17.71 ± 1.017 amino acids; n= 7; p < 0.0001,
unpaired two-tailed Student’s t-test). Seven of the eight IgD+
NLPHL cases expressed a member of the VH3 family, compared
with one of the seven IgD− NLPHL cases. Furthermore, cases
with extraordinarily long CDR3 had characteristic VDJ-
recombinations (frequently D3-3*01-JH6 rearrangements, see
Table 2).
BCRs derived from IgD+ LP cells react with Moraxella spp.
Overall, 6/8 IgD+ NLPHL-derived BCRs (four [#3, #6, #9, and
#10] from the screening cohort and two [#13 and #14] from the
validation cohort) reacted against M. catarrhalis lysates (Fig. 1a)
Table 1 Characteristics of the NLPHL patients included in this study.









1 m 52 Relapse Axillary No No No No
2 m 15 Relapse Supraclavicular No No No No
3 m 14 2nd relapse Cervical Yes yes No Yes
4 m 65 First manifestation Cervical No No No Yes
5 f 37 First manifestation Retroperitoneal No No No No
6 m 15 Relapse Cervical Yes Yes No Yes
7a m 51 2nd relapse Axillary No No No No
7b m 51 2nd relapse Axillary No No No No
8a m 40 Primary
progressive
Abdominal No No No No
8b m 40 Primary
progressive
Abdominal No No No No
9 m 42 Relapse Inguinal Yes Yes No Yes
10 m 12 2nd relapse Inguinal Yes Yes No Yes
11 m 15 First
manifestation
Cervical Yes No Yes Yes
12 m 31 First manifestation Cervical No No No Yes
13 m 18 First
manifestation
Cervical Yes Yes No Yes
14 m 30 First
manifestation
Parotid Yes Yes No Yes
15 f 16 First
manifestation
Axillary Yes No No No
Bold: IgD+ NLPHL; cases 7 and 8: (a) NLPHL, (b) histological transformation into DLBCL in the same lymph node.
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and the M. catarrhalis strain ATCC 43617 RO 108 (data not
shown), whereas one IgD+ NLPHL (#11) reacted with a M.
osloensis lysate (Fig. 1a, Supplementary Information and Sup-
plementary Fig. 2). No BCRs derived from IgD− NLPHL cases
reacted with either M. catarrhalis or M. osloensis. In Western
blots of M. catarrhalis lysates, the BCRs derived from IgD+
NLPHL cases detected a target antigen of 150–160 kDa (Fig. 1b,
Supplementary Figs. 3 and 4). M. catarrhalis outer membrane
vesicles contain two potential candidate antigens that have
molecular weights >150 kDa: Moraxella IgD-binding protein
(MID/hag) and DNA-directed RNA polymerase subunit beta’ of
M. catarrhalis (RpoC)16. The MID/hag monomer has a molecular
weight of 200 kDa, whereas the multimer has a molecular weight
of ~800 kDa under non-reducing conditions (Supplementary
Fig. 3)17,18. In contrast, the Moraxella-reactive BCRs (#3, #6, #9,
and #10) recognized a protein of 150–160 kDa (Supplementary
Fig. 4), which excludes MID/hag as their target. Moreover, the
Moraxella-reactive BCRs did not bind to recombinant fragments
of MID/hag in Western blots (data not shown). The specific
binding of the BCRs with recombinant RpoC was demonstrated,
both by ELISA and Western blots (Fig. 1b, c), confirming that
RpoC was the 150–160 kDa band detected in the M. catarrhalis
lysate. The dominant epitope of RpoC-reactive BCRs was span-
ning from amino acid 600–1130 of RpoC, which could be further
narrowed down to amino acids 851–865 (Fig. 1d and Supple-
mentary Fig. 5).
IgD+ status of NLPHL was significantly associated with
reactivity of recombinant Fabs against M. species (p= 0.007;
Fisher’s exact test) and M. catarrhalis RpoC (p= 0.0014; Fisher’s
exact test). In contrast to NLPHL, none of the recombinant BCRs
derived from 12 DLBCL, 11 primary central nervous system
lymphomas, 10 mantle cell lymphomas, and 12 chronic
lymphocytic leukemia cases reacted with M. catarrhalis RpoC
(Supplementary Fig. 6). Additionally, for IgD− NLPHL two
autoantigens were identified as targets of BCRs of LP-cells
(Supplementary Fig. 7). Several representative dot and western
blots are shown in supplementary (Supplementary Figs. 16–22).
Restriction to certain MHC II classes in IgD+ NLPHL. Seven of
the eight IgD+ NLPHL patients, including all six cases with an
RpoC-specific BCR, had HLA-DRB1*04 or HLA-DRB1*07
haplotypes (Table 3). The presence of HLA-DRB1*04 or HLA-
DRB1*07 was significantly associated with reactivity against
Moraxella species (p= 0.0256; two-tailed Fisher’s exact test), and
with reactivity against M. catarrhalis RpoC (p= 0.044; two-tailed
Fisher’s exact test). For M. catarrhalis RpoC five T-cell epitopes,
with high SYFPEITHI scores, were predicted for HLA-DRB1*04,
and six epitopes were predicted for HLA-DRB1*07 (Supple-
mentary Table 2), suggesting that these haplotypes can provide
cognate follicular T-cell help for RpoC-specific B cells.
NLPHL patients show high-titer anti-RpoC-serum antibodies.
Serum antibodies againstM. catarrhalis RpoC were detected in 2/2
patients with IgD+ RpoC-specific BCRs within the screening
cohort, at a titer of 1:3200, which belonged to the IgG1/κ subclass







JH/JL gene DH gene length
CDR3 (AA)
Junction
1 Neg VH1-3-01 91.3 Yes JH4*02 D3-10*01 20 CAREVRPPRIIMIWGVGLLDFW
1 Neg VK1-27*01 97.5 Yes JK4*01 – 9 CQKYNSAPLTF
2 Neg VH1-46*01 87.5a Yes JH2*01 D3-16*02 15 YYCARDEGDIRRYFDLW
2 Neg VK3-15*01 92.8 Yes JH5*01 –
D3-3*01
10 CQQYNYWPPVTF
3 Pos VH3-11*01 95.1 Yes JH6*03 D3-3*01 26 CARVAGAAGRNYNYWSGYWEDYYFMDVW
3 Pos VK2D30*01 99.3 Yes JH4*01 – 9 CMQGTHWPR
4 Neg VH4-31*01 99.2 Yes JH3*02 D3-22 19 CARGPPPYDSSGYYSHGLDIW
4 Neg VK1-37 99.3 Yes JK3*01 – 8 GQRTYNAPRF
5 Neg VH4-39*01 100 No JH6*04 D6-19*01 15 CASMGAVAGMMFGMDVW
5 Neg VK1-5*03 96 Yes JK1*01 – 8 CQEYNSYWTF
6 Pos VH3-07*01 95.5 Yes JH6*04 D3-3*01 26 CAREVLRWGGSYDFWSNYYEDYFALDVW
6 Pos VK-1D43*01 98.5 Yes JK3*01 – 10 CQQYYSTPPFTF
7a Neg VH1-69 86.4 Yes JH5*02 D6-19*01 17 CARDYSRGVCGPRYGMDVW
7a Neg VK3-11*01 93.8 Yes JK4*01 – 9 CQQRSNWPPAF
7b Neg VH1-69 84.7 Yes JH5*02 D6-19*01 17 CAREYSRGVCGPRYGMDVW
7b Neg VK3-11*01 90.3 Yes JK4*01 – 9 CQQRSNWPPAF
8a Neg VH3-30 89.9 Yes JH6*02 D2-15*01 22 CARKGGDPVLALFVPNFAMDVW
8a Neg VK1-33*01 91.6 Yes JK4*01 – 9 CQQYNSLPITF
8b Neg VH3-30 89.0 Yes JH6*02 D2-15*01 22 CARKGGDPVLAVFVPNFALNVW
8b Neg VK1-33*01 91.1 Yes JK4*01 – 9 CQQYNSLPITF
9 Pos VH3-48*03 82.0 Yes JH6*02 D3-3*01 30 CAKSVLTAKSGKSYKFWNNYHEDYHYYLMDVW
9 Pos VK1-27*01 87.1 Yes JK3*01 – 10 CQNYNTVPLTF
10 Pos VH4-59*01 86.4b Yes JH6*03 D3-3*01 33 CATVDPTVVEGRVKYYDFWSGYYGTDQRYYYMDVW
10 Pos VL3-21*01 92.8 Yes JL2*01 - 11 CQVWDSSSDHPVF
11 Pos VH3-11*01 95.5 Yes JH6*02 D3-3*01 30 CARLLTSEGSRKYYDFWSNYWEGYQYYTMDVW
11 Pos VK2-28 99.2 Yes JK3*03 – 9 CMQGLQTVFTF
12 Neg VH4-34 100 No JH5*02 D3-10*01 16 CARGPYLWFGERGWFDPW
12 Neg VK1-5*01 94 Yes JK2*03 – 9 CQQYNSYPYCF
13 Pos VH3-11*01 83.0 Yes JH6*03 D3-3*01 26 CARLCAAGGRSYDFWSGYYENYFYMEVW
13 Pos VK1-5*01 86.7 Yes JK4*01 – 10 CQQYSGSSRVTF
14 Pos VH3-11*01 87.6 Yes JH6*02 D3-3*01 30 CARLIEAGGVGKHYDFWSGYYTVDYYYGMDVW
14 Pos VK1-43*01 94.3 Yes JK4*01 – 10 CQQYYSTPPLTF
15 Pos VH3-30*04 89.8 Yes JH6*02 D3-3*01 33 CARTTWVGVVGRIKYYDFWSGYHGTGMEYYTMDVW
15 Pos VL9-49*01 98.1 Yes JL3*02 – 12 CGADHGSGSNFWVF
15 Pos VK1-17*01 94.33 Yes JK4*01 – 10 CLQHNSYPRLTF
Bold: IgD+ NLPHL; all cases had functional IgV genes. For case 15 two functional light chains were amplified. For somatic mutation a threshold of 0.5% was used.
a Insertion in FR3 (AGAAAT).
bWith deletion of 3 nt in CDR2.
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(Fig. 1e). High-titer, anti-M. catarrhalis-RpoC antibodies were
found in 20/98 NLPHL patients enrolled in clinical trials con-
ducted by the German Hodgkin Study Group (GHSG) (Fig. 2a),
which is representative of the general population of NLPHL
patients. All anti-M. catarrhalis-RpoC antibodies were of IgG class
and predominantly of the IgG1 subclass (Fig. 2b), thus probably
not related to the IgD+ LP cell clone. However, in each patient
with serum antibodies against RpoC, these were light chain
restricted (Fig. 2b), indicating a clonal origin and presumably a
relation to the initiating event of NLPHL. The titers ranged from
1:800 to 1:3,200 (Fig. 2c). When applying a titer higher than 1:400
as cut off for positivity, no healthy control or patient with cHL or
THRLBCL was positive. High titer (>1:400) serum antibodies
against M. catarrhalis RpoC were associated with NLPHL (p <
0.0001; Fisher’s exact test). Low-titer RpoC-antibodies were
detected in the serum of 9/188 healthy controls (Supplementary
Fig. 8) and in 10/100 patients with classical HL (Fig. 2d), with
maximum titers of 1:200 (Fig. 2e, Supplementary Figs. 9 and 10).
Streptococcus pyogenes
IgD expression of LP-cells:
200 kDa -
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Fig. 1 Reactivity of recombinant IgD+ LP cell-derived Fabs with bacterial lysates. a Representative Immuno-dot blots of bacterial lysates. NLPHL-derived
recombinant Fabs of six cases bound to lysates ofM. catarrhalis, and of one case to lysate of M. osloensis. Eight cases showed no reactivity against bacterial
lysates. All sixM. catarrhalis-reactive recombinant Fabs (#3, #6, #9, #10, #13, and #14) and the oneM. osloensis-reactive Fab (#11) were derived from IgD+
NLPHL cases. b Representative Western blot of recombinant C-terminally FLAG taggedM. catarrhalis RpoC expressed in HEK293 cells confirmed reactivity
of lymphoma Fabs #3, #6, #9, #10, #13, and #14 with the recombinant bacterial antigen. A recombinant C-terminally FLAG-tagged SMCHD1 fragment was
used as negative control. c ELISA with recombinant C-terminally FLAG-tagged M. catarrhalis RpoC as a coat demonstrated specific reactivity of Fabs
derived from LP cells of six patients (#3, #6, #9, #10, #13, and #14) against recombinant RpoC. Values are mean ± SD. d Determination of the epitope of
RpoC recognized by IgD+ NLPHL Fabs. Recombinant Fabs #3, #6, #9, and #10 bind AA 600–1130 ofM. catarrhalis RpoC. Values are mean ± SEM. e Serum
reactivity against RpoC in patients from whom recombinant NLPHL Fabs were derived. The two IgD+ NLPHL patients with RpoC-reactive recombinant
lymphoma Fabs (#3 and #6) had higher anti-RpoC-antibody serum titers (1:1600) than a healthy control with anti-RpoC-antibodies (1:200). The IgD+
NLPHL patient with the M. osloensis-specific Fab (#11) had no serum anti-RpoC-antibodies. Values are mean ± SD. Experiments were independently
repeated three times. f: Immunoglobulin classes and subclasses and light chains of serum RpoC antibodies from the two patients with RpoC-reactive BCR
of the LP cells (#3 and #6) and a seropositive healthy control. Patients #3 and #6 both show a predominance of IgG1/κ. The healthy control had
additionally anti-RpoC-antibodies of IgM class and in contrast to patients #3 and #6 no clear light chain restriction. Values are mean ± SD.
g Representative Western blot of FLAG-tagged M. osloensis SUCLG1 expressed in HEK293 cells confirms reactivity of lymphoma Fab #11 with the
recombinant bacterial antigen. h ELSIA with recombinant M. osloensis SUCLG1 as a coat demonstrated specific reactivity of Fabs derived from LP cells of
patient #11 against recombinant SUCLG1. Values are mean ± SD. Data in a–c, e, and f are representative of three independent experiments each; data in
d, g, and h are representative of two independent experiments.
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RpoC-antibody-seropositive NLPHL patients (n= 20) did not
differ in their clinical characteristics (age, gender, stage, site of
manifestation, progression-free, and overall survival) from RpoC-
antibody-seronegative NLPHL patients (Fig. 2f and data not
shown). Unfortunately, the IgD-status was not available for this
cohort. In the sera from 50 patients with THRLBCL, which
represents a closely related entity to NLPHL, no RpoC-antibodies
were found (Fig. 2g). Summarizing, anti-RpoC-antibodies were
Table 3 MHC alleles of NLPHL.
Case HLA-A HLA-B HLA-DRB1 HLA-DQB1 HLA-DQA1
1 A*11/A*24 B*44/B*51 DRB1*01:01:01/DRB1*11:01:01 DQB1*03:01:01/DQB1*05:01:01 DQA1*01:05:01/DQA1*05:05:01
2 A*01/A*02 B*40/B*49 DRB1*01:01:01/DRB1*11:02:01 DQB1*03:19/DQB1*05:01:01 DQA1*01:05:01/DQA1*05:05:01
3 A*03/A*32 B*44/B*51 DRB1*04:01:01/DRB1*11:01:01 DQB1*03:01:01/DQB1*03:02:01 DQA1*03:01:01/DQA1*05:05:01
4 A*02/A*31 B*18/B*56 DRB1*04:01:01/DRB1*15:01:01 DQB1*06:02:01/DQB1*03:02:01 DQA1*01:02:01/DQA1*03:01:01
5 A*03/A*32 B*15/B*47 DRB1*11:01:01/DRB1*11:01:01 DQB1*03:01:01/DQB1*03:02:01 DQA1*03:01:01/DQA1*05:05:01
6 A*30/A*32 B*13/B*35 DRB1*04:07:01/DRB1*07:01:01 DQB1*02:02:01/DQB1*03:01:01 DQA1*02:01/DQA1*03:03:01
7 A*01/A*02 B*08/B*08 DRB1*11:01:01/DRB1*15:01:01 DQB1*06:02:01/DQB1*03:01:01 DQA1*01:02:01/DQA1*05:05:01
8 A*02/A*33 B*14/B*35 DRB1*01:02:01/DRB1*12:01:01 DQB1*03:01:01/DQB1*05:01:01 DQA1*01:01:02/DQA1*05:05:01
9 A*02/A*11 B*35/B*44 DRB1*04:01:01/DRB1*08:01:02 DQB1*04:02:01/DQB1*03:01:01 DQA1*03:01:01/DQA1*04:01:01
10 A*02/A*25 B*44/B*18 DRB1*04:01:01/DRB1*14 DQB1*03:01:01/DQB1*05 DQA1*01:04:01/DQA1*03:03:01
11 A*02/A*03 B*07/B*50 DRB1*07/DRB1*07 DQB1*02/DQB1*02 –
12 A*02/A*03 B*35/B*58 DRB1*01:01:01/DRB1*04:01:01 DQB1*03:02:01/DQB1*05:01:01 DQA1*01:05:01/DQA1*03:01:01
13 A*01/A*02 B*08/B*44 DRB1*03:01:01/DRB1*07:01:01 DQB1*02:01:01/DQB1*05:02:01 DQA1*02:01:01/DQA1*05:01:01
14 A*02/A*11 B*07/B*35 DRB1*07:01:01/DRB1*13:02:01 DQB1*03:03:02/DQB1*06:04:01 DQA1*01:02:01/DQA1*02:01:01
15 A*02/A*31 B*40/B*57 DRB1*04:01:01/DRB1*07:01:01 DQB1*03:01:01/DQB1*03:03:02 DQA1*02:01:01/DQA1*03:01:01
Bold: IgD+ NLPHL.
3 Anti-RpoC in NLPHL serum cohort
Anti-RpoC seropositive NLPHL case
Anti-RpoC titer of seropositive NLPHL (GHSG) case
Time [month]
Log-Rank test: p = 0.13
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Fig. 2 Serological responses against RpoC of M. catarrhalis in NLPHL, cHL, and THRBCL. a Sera of patients with NLPHL (diluted 1:100) were tested for
antibodies against RpoC of M. catarrhalis. b Analysis of Ig classes (left), IgG subclasses (middle), and light chains (right) of serum-antibodies against RpoC
ofM. catarrhalis in patients with NLPHL. The anti-RpoC antibodies were exclusively of the IgG class, mostly IgG1, and showed light chain restriction. c Titers
of anti-RpoC antibodies in seropositive patients with NLPHL. The curves represent OD at 490 nm of different serum dilutions. Patients with NLPHL had
titers between 1:800 and 1:3200. d Sera of patients with cHL (diluted 1:100) were tested for antibodies against RpoC of M. catarrhalis. e Seropositive
patients with cHL had RpoC-antibody titers of up to 1:200. f PFS and OS of patients with NLPHL with and without RpoC-antibodies. No significant
difference was observed for PFS (p = 0.13, Log-Rank-test) and OS (p = 0.26, Log-Rank-test). g Sera of patients with THRBCL (diluted 1:100) were tested
for antibodies against RpoC, but all patients with THRBCL were seronegative for RpoC-antibodies. Serum of a seropositive NLPHL patient served as positive
control. h Scatter blot for comparison of RpoC-antibodies in sera of patients with NLPHL, cHL, or THRBCL, and healthy controls. Data in a and d are
representative of three independent experiments, data in b, c, e, g, and h are representative of two independent experiments.
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frequently found in NLPHL patients, but not in patients with
related lymphomas or healthy controls (Fig. 2h).
RpoC and MID/hag induce additive stimulation. Since we
hypothesized that specific stimulation of the LP cell BCR by RpoC
contributes to the lymphomagenesis of IgD+ NLPHL, patient-
derived RpoC-specific BCRs were functionally investigated. At
baseline, neither recombinant M. catarrhalis RpoC nor MID/hag
resulted in increased proliferation of the IgD− DEV cell line,
which is the only available NLPHL cell line (not shown). Similar
results were observed for DEV cells stably expressing transfected
BCRs without reactivity against RpoC. In contrast, RpoC stimu-
lation resulted in the significantly increased proliferation of DEV
cells that stably expressed RpoC-reactive IgD+-BCRs (Fig. 3a, b).
Likewise, when MID/hag fragments 2/3 or 3 were applied by
itself, already a significantly increased proliferation rate was
observed (Supplementary Fig. 11). However, proliferation was
further increased by the costimulation with RpoC and the MID/
hag fragments 2 and 3, which contain the IgD-binding region
(amino acids 920–1200) (Fig. 3a–c and Supplementary Fig. 11).
This additive effect of MID/hag stimulation was not observed
when DEV cells were transfected with an RpoC-reactive BCR of
the IgG or IgM subtype (Fig. 3a, b). Accordingly, RpoC and MID/
hag stimulation resulted in the strong activation of the BCR-
signaling pathway, as determined by phosphorylation of key
BCR-signaling factors (pTyr525/526 spleen tyrosine kinase
[SYK], pTyr96 B-cell linker [BLNK], pTyr759 phosphoinositide-
specific phospholipase C [PLC]γ2, and pTyr223 Bruton’s tyrosine
kinase [BTK]) in DEV cells that stably expressed RpoC-reactive
IgD+ BCRs (Fig. 3c). The activation of the BCR pathway was
associated with a significant increase in MYC expression (Fig. 3c).
Additionally, the NF-κB pathway was activated after stimulation
with RpoC and MID/hag (Supplementary Fig. 12). Activation was
also shown by flow cytometric analysis of cytoplasmic calcium
levels in DEV cells that stably expressed RpoC-reactive IgD+
BCRs by an increase in the intracellular calcium levels after
incubation with M. catarrhalis RpoC, which could be further
increased by coincubation with RpoC and MID/hag, but was not
induced by a control antigen (MAZ, Supplementary Fig. 13).
Antigen/drug conjugates target RpoC-reactive LP cells. By
using a synthetic FITC-conjugated RpoC peptide, which con-
tained the binding epitope, the binding and internalization of
RpoC into DEV cells that stably expressed RpoC-reactive BCRs
could be measured using flow cytometry (Fig. 3d). In a LDH
release assay, RpoC conjugated to a truncated form of Pseudo-
monas aeruginosa exotoxin A (RpoC/ETA’), was found to be
cytotoxic against the DEV cell line that stably expressed RpoC-
specific BCRs but had no effects on non-transfected DEV cells or
on DEV cells that expressed BCRs specific for antigens other than
RpoC (Fig. 3e). As shown by a trypan blue exclusion assay, 50%
of the NLPHL cells expressing an RpoC-specific BCR died within
48 h after incubation with RpoC/ETA’ (Supplementary Fig. 14).
In support of these results, an increase in the number of apoptotic
cells was detected by an AnnexinV/propidium iodide assay
(Fig. 3f).
Autoantigenic targets of BCRs derived from IgD− LP cells.
Two autoantigens, human ribosomal protein S27a (RPS27a, for
NLPHL #1, AA1-AA95) and human pyruvate carboxylase (for
NLPHL #5, AA1030-AA1178), were identified as antigenic targets
of the BCRs of two individual IgD− NLPHL cases. Reactivity of
the respective Fabs was confirmed by ELISA using recombinantly
expressed RPS27 and pyruvate carboxylase with C-terminal
FLAG-tag expressed in HEK293 cells (Supplementary Fig. 7A,
B). ELISAs with different fragments of pyruvate carboxylase
revealed AA1111–AA1177 as the binding region of the recom-
binant Fab of patient #5 (Supplementary Fig. 7C). When com-
paring the identified antigens from the patients with autoreactive
NLPHL-BCRs with those of healthy controls by Western-blot no
obvious difference was detectable (Supplementary Fig. 7D).
However, when comparing them by isoelectric focusing (IEF) a
different electric charge of pyruvate carboxylase exclusively in
patient #5 was observed (Supplementary Fig. 7E). This different
electric charge was not altered after treatment with alkaline
phosphatase (Supplementary Fig. 7F), but recombinant biotini-
dase pretreatment ahead of IEF resulted in the disappearance of
the different electric charge, confirming a differential biotinyla-
tion of pyruvate carboxylase of patient #5 (Supplementary
Fig. 7G). The hypobiotinylated pyruvate carboxylase might con-
tribute to its immunogenicity in patient #5. Autoreactive BCRs
contributing to lymphomagenesis by chronic stimulation due to
alternative secondary modifications have previously been descri-
bed in MGUS, Waldenström macroglobulinemia, multiple mye-
loma, and primary central nervous system lymphoma19–22.
Pyruvate carboxylase is a highly conserved gene, and has been
identified as an antigen recognized by BCRs of CLL23.
Discussion
Here, we describe a distinct subtype of NLPHL, with IgD+ LP
cells, characteristically long IgVH CDR3s (median 30 amino
acids), a high frequency of IgV gene mutations, and characteristic
VDJ-recombination. IgD+ NLPHL previously defined a unique
clinical NLPHL subset, which primarily affected the cervical
lymph nodes of male adolescents2,24. Our results provide evi-
dence that chronic antigenic simulation by a common bacterium
contributes to lymphomagenesis in NLPHL25. Antigens produced
by M. catarrhalis or M. osloensis were specifically recognized by
recombinant BCRs derived from 7/8 NLPHL cases with IgD+ LP
cells. Further analysis identified M. catarrhalis RpoC as the spe-
cific antigen for six M. catarrhalis-reactive BCRs and SUCLG1 as
specific antigen for the single M. osloensis-reactive BCR. M. cat-
arrhalis-derived RpoC bound specifically to the antigen-binding
sites of IgD+ NLPHL-derived BCRs, which were specific for
Moraxella, with no cross-reactivity against >200 pathogens,
including various bacterial, fungal, parasitic, and viral pathogens.
Likewise, BCRs from 45 B-NHLs, including DLBCL, primary
central nervous system lymphoma, mantle cell lymphoma, and
chronic lymphocytic leukemia, did neither bind to the M. cat-
arrhalis lysate nor to RpoC. The presence of high-titer M. cat-
arrhalis-RpoC antibodies in NLPHL serum samples suggests
generally an adaptive humoral immune response against M.
catarrhalis. The fact that these antibodies were predominantly of
the IgG1 subclass and in addition light chain restricted, suggests a
clonal B-cell expansion apart from the LP cell clone, that
underwent class switch recombination and plasmocytic differ-
entiation. These findings suggest that naïve IgD+ B cells become
activated in an adaptive humoral immune response against M.
catarrhalis and represent the precursors of LP cells.
M. catarrhalis is a widespread, Gram-negative bacterium that
causes recurrent airway infections and otitis media26. M. catar-
rhalis additionally expresses the IgD-binding protein MID/hag,
a bacterial autotransporter that binds specifically to the IgD
Fc region and activates IgD+ B cells in a superantigenic
manner27–29. Of interest, the outer membrane vesicles of M.
catarrhalis contain both MID/hag and RpoC17 and activate B
cells28, suggesting that M. catarrhalis can stimulate IgD+ LP cells
in an additive manner, through RpoC binding to the antigen-
binding region and through MID/hag binding to the Fc region of
the BCR (Fig. 4). This result implies the combined antigenic and
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Fig. 3 Costimulation of different types of LP cells by RpoC and MID/hag. a Tetrazolium proliferation assay with the transfected DEV cells expressing
recombinant BCRs with different RpoC-reactive Fab fragments and Fc fragments of either IgD or IgG class. Stimulation with RpoC resulted in significant
proliferation, and costimulation with MID/hag fragments 2 and 3 resulted in strong further increase of proliferation in cell lines expressing BCR of IgD class,
e.g. transfected DEV expressing IgD+ BCR #3 stimulated by rec. human SLP2 vs. rec. M. catarrhalis RpoC: p < 0.00001 (DF= 32, q= 17.99); DEV
expressing IgD+ BCR #3 stimulated by rec. human SLP2 vs. rec. M. catarrhalis RpoC and MID/hag 2&3: p < 0.00001 (DF= 32, q= 46.22). b In a
Tetrazolium assay stimulation with RpoC resulted in increase of proliferation in DEV cells expressing RpoC-reactive BCRs, but not in DEV cells expressing
non-RpoC-reactive BCRs. In IgD+ DEV cells with RpoC-reactive BCR incubation with MID/hag 2 and 3 resulted in a significant increase of proliferation,
whereas costimulation with MID/Hag fragments 2 and 3 and the control antigen SLP2 had no additive effect. DEV expressing IgD+ BCR #6 stimulated by
rec. human SLP2 vs. rec. M. catarrhalis RpoC: adjusted p < 0.0001 (DF= 56, q= 7.321) and DEV expressing IgD+ BCR #6 stimulated by rec. M. catarrhalis
RpoC and MID/hag 2&3 vs. DEV expressing IgM+ BCR #6: p < 0.00001 (DF= 56, q= 29.44). Values in a and b are mean ± SEM. Two-way ANOVA
with Tukey’s multiple comparisons were performed, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. Experiments were independently repeated three times.
c Activation of the BCR-signaling pathway. Representative Western blot analysis of the BCR signaling pathway shows a strong activation by RpoC and even
stronger by coincubation with RpoC and MID/hag in DEV cells transfected to express an RpoC-reactive IgD+ BCR. The incubation with RpoC, RpoC&Mid/
Hag, or anti-IgM/IgD antibody results in the upregulation of the activated isoforms pTyr525/526 SYK, pTyr96 BLNK, pTyr759 PLCγ2, and pTyr223 BTK
and induced overexpression of MYC. d Binding and internalization of RpoC/FITC into LP cells. RpoC/FITC bound to DEV cells transfected to express
recombinant BCR of case #6 with RpoC-reactivity, but not to DEV cells transfected to express recombinant BCR of case #5. After 60min internalization of
RpoC/FITC into DEV cells with the RpoC-specific BCR #6 was observed. Control CD30/FITC neither bound to DEV cells nor was internalized. e Dose-
dependant cytotoxic effects by ETA’ toxin-conjugated RpoC dependent on expression of RpoC-reactive BCRs on LP cells. Specific cytotoxicity evoked by
RpoC/ETA’ was observed in the DEV cell line expressing the RpoC-reactive BCR of patient #3 (left), but not in the one expressing the autoreactive BCR of
patient #5 (right). f Apoptosis induced by ETA’ toxin-conjugated RpoC dependent on expression of RpoC-reactive BCRs on LP cells. Characterization of
DEV cells stably transfected to express IgD+ recombinant BCRs with (above, from case #3) or without (below, from case #8a) reactivity to M. catarrhalis
RpoC by Annexin-V/FITC and propidium iodide staining after 24 h cultivation in the presence of RpoC/ETA, MAZ/ETA, or RpoC/ETA together with MID/
hag. RpoC/ETA induced specifically apoptosis in the DEV cell line with RpoC-reactive BCR. Data in a–c and f are representative of three independent
experiments, data of d and e are representative of two independent experiments.
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superantigenic stimulation of RpoC-reactive BCRs, which is
supported by our in vitro model using the DEV cell line to
express IgD+ patient-derived RpoC-specific BCRs. The RpoC-
induced increase in proliferation was only observed in DEV cells
transfected with RpoC-reactive BCRs. The combination of RpoC
and MID/hag fragments that contained the IgD-binding domain
resulted in the strong and additive BCR pathway activation and
proliferative effects in DEV cells that expressed RpoC-reactive
IgD+ BCRs.
A potential role for superantigen-driven germinal center
reactions in the generation of highly mutated IgV regions in so-
called IgD-only B cells has previously been proposed30. The high
mutation load in IgVH genes isolated from IgD+ NLPHL patients
identifies a germinal center origin for the respective LP cells,
which would require cognate T-cell help. This is supported by the
presence of “permissive” HLA-DRB1*04/*07 haplotypes. Indeed,
several high-affinity T-cell epitopes are predicted for these hap-
lotypes, suggesting that these haplotypes can provide cognate
follicular T-cell help for RpoC-specific B cells. Thus, in addition
to the two M. catarrhalis-derived stimuli, a third stimulus may be
provided in respective individuals by antigen-specific CD4+ T-
helper cells, resulting in the extensive proliferation of B cells with
a specificity for M. catarrhalis RpoC. During germinal center
reactions, the chronically stimulated B cells likely acquire trans-
forming events, resulting in the development of the malignant
clone4. Because all RpoC-reactive BCRs derived from LP cells
were IgD+, the additional stimulation by the MID/hag protein is
likely to be essential for the pathogenetic role played by M. cat-
arrhalis in this scenario, as this finding indicates that the LP
precursor cells are selected to retain IgD expression31–33. Con-
tributions to lymphomagenesis from the chronic stimulation by T
helper cells that have been activated by infectious pathogens or
autoantigens have been demonstrated for some other lympho-
mas32–34. However, with the exception of hepatitis C virus, the
target antigens of the BCRs from these lymphomas have either
not been defined or have been shown to be autoantigens, and a
combined antigen-specific and superantigenic stimulation, as has
been identified here for NLPHL, has never been reported.
In contrast with NLPHL, no RpoC-antibodies were observed in
the sera of a cohort of 50 THRLBCL patients. THRLBCL is an
aggressive B-cell lymphoma that is closely related to NLPHL.
Transformations of NLPHL into THRLBCL-like cases have been
observed. However, the lack of RpoC-antibodies in THRLBCL
patients suggests a different pathogenic mechanism than that
observed for the Moraxella-induced NLPHL subtype. Further-
more, NLPHL cases that are Moraxella sp.-induced do not pre-
sent with a THRLBCL-like morphology. Given recent reports
from retrospective analyses regarding less intensive treatments
and active surveillance strategies for NLPHL35, the results of the
present study might further raise discussions regarding how to
treat this Moraxella sp.-induced NLPHL subgroup, in particular.
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Fig. 4 Presumable role of M. catarrhalis in the pathogenesis of IgD+ NLPHL. Costimulation of B cells characterized by IgD+ BCR and extraordinary long
CDR3s by M. catarrhalis RpoC via the Fab fragment and MID/hag via the Fc fragment of their BCR. Naïve, mature IgD+ B cells with a BCR specific for RpoC
encounter M. catarrhalis outer membrane vesicles. Binding of RpoC to the Fab and of MID/hag to the Fc region of membranous IgD induces activation of
RpoC-specific IgD+ B cells, which is supported by CD4+ T cells particularly in patients with an HLA-DRB1*04 or DRB1*07 haplotype. The persistent or
recurrent presence of M. catarrhalis presumably induces a germinal center reaction resulting in differentiation to memory B cells and plasmablasts and
production of class-switched anti-RpoC serum antibodies and apoptosis of some germinal center cells due to disadvantageous mutations. The co-
stimulatory effect of MID/hag through binding to the Fc part of IgD selects for retention of IgD on a fraction of the stimulated germinal center B cells.
Meanwhile a clone acquires mutations in proto-oncogenes, tumor suppressor genes as well as chromosomal translocations and may transform into LP
cells. However, the transformed IgD+ LP cells still gain growth advantage by the interaction of their BCRs with M. catarrhalis RpoC and MID/hag.
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and/or vaccination strategies could be used to prevent relapses of
Moraxella sp.-induced NLPHL. Finally, the shared, specific BCR
antigen found in IgD+ LP cells could be therapeutically exploited
as the targeting moiety for different therapeutic formats, such as
antigen/toxin conjugates, bispecific CD3 or CD16 constructs or
CAR-T cells, resulting in the selective delivery of a therapeutic
payload to RpoC-reactive B cells and leaving other B cells
unaffected36.
Methods
Study samples. The study was approved by the local ethics committees of the
Universities in Frankfurt and Homburg. Frozen tissue sections of NLPHL speci-
mens from the Dr. Senckenberg Institute of Pathology, Goethe University Hospital,
Frankfurt/Main, Germany, from the Department of Pathology, Tampere Uni-
versity, Tampere, Finland, from the Institute of Pathology, CHUV Lausanne,
Switzerland, and from the Department of Pathology, Uppsala University Hospital,
Sweden, were analyzed. Informed consent of the patients was obtained in accor-
dance with the Declaration of Helsinki. Sera of patients with NLPHL and sera of
healthy controls were obtained at the medical school Homburg/Saar, Germany.
Moreover, sera of patients with cHL or NLPHL were obtained from the HD13
(ISRCTN63474366), HD14 (ISRCTN04761296), HD15 (ISRCTN32443041), HD16
(NCT00736320), HD17 (NCT01356680) and HD18 (NCT00515554) trials of
German Hodgkin Study Group (GHSG) as control and validation cohort37–40. Sera
from patients with THRLBCL were obtained from the RICOVER (NCT00052936),
Hi-CHOEP (NCT00129090), UNFOLDER (NCT00278408), FLYER
(NCT00278421), CHOP-R-ESC (NCT00290667) trials of the German High-Grade
Non-Hodgkin Lymphoma Study Group (DSHNHL)41–44.
Laser microdissection and IgV region gene PCR. Single, clearly identifiable LP
cells were microdissected with an ultraviolet laser (PALM microdissection system,
Zeiss Axiovert 200M microscope), pooled in groups of 30 cells and resuspended in
18 µl 1x PCR buffer and digested with 2 µl of proteinase K (Roche, Grenzach,
Germany) at 55 °C for 4 h, followed by enzyme inactivation at 95 °C for 10 min.
The LP cell lysates were subjected to two rounds of VH-, Vκ-, and Vλ-specific
seminested PCRs (30 and 44 cycles in the first and second round of PCR,
respectively) using IgV family-specific primers and J primer mixes, and Expand
high fidelity PCR kit (Roche) as described by Küppers et al. 45.
Expression of recombinant BCRs. The amplified IgV region genes were
sequenced and analyzed with IMGT-V-Quest for functionality, V, D, and J seg-
ment usage and indications for somatic mutations. If both a functional heavy
and light chain variable region gene was amplified, the IgV region genes were
cloned into TOPO Zero-Blunt vector (Invitrogen Life Technologies, Darmstadt,
Germany)46. IgV gene fragments were re-extended at the 5′ and 3′ ends according
to the proper immunoglobulin germline genes. Complete IgV genes were inserted
via ApaLI and XhoI for IgVκ or IgVλ in front of a κ-constant or λ-constant region
gene, respectively, and via NcoI and BstEII for IgVH in front of a γ-1 constant
region gene into a modified pCES-1 vector for expression of the Fab fragments47.
Fabs were expressed and purified23.
Antigen screening. To screen for potential reactivity of Fabs against bacterial
antigens, heat-inactivated lysates of 13 different bacterial strains or patient isolates
including M. catarrhalis, M. osloensis, M. nonliquefaciens, Streptococcus pneumo-
niae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus,
coagulase-negative staphylococci, Klebsiella pneumoniae, Enterobacteriacae,
Escherichia coli, Acinetobacter radioresistens, Neisseria spp., as well as DNA from
M. catarrhalis and osloensis isolated from a patient, were provided by the Institute
of Medical Microbiology and Hygiene of the University of Saarland, Homburg/
Saar, Germany. Inactivated lysates of M. catarrhalis strain ATCC 43617 RO 108
and lysates of Bartonella henselae strain Marseille (Bartonella adhesin A positive),
were provided by the Institute of Medical Microbiology and Infection Control of
the Hospital of the Goethe University Hospital, Frankfurt/Main (Supplementary
Table 3), were spotted onto PVDF membranes each with a dose of 10 µg. The dot
blots of bacterial lysates were blocked in 10% (w/v) non-fat dry milk powder in
TBST [TBS, 0.1% (v/v) Tween 20] at 4 °C overnight, washed twice in TBST and
incubated for 1 h with the individual Fabs, each at a concentration of 10 µg/ml.
Following three 30-min TBST washes and subsequent incubation for 1 h at room
temperature with biotinylated goat anti-human heavy and light chain Fab antibody
(DIANOVA, 109-065-088) at a dilution of 1:5000 (v/v) the arrays and blots were
incubated for 10 min at room temperature with Strep-POX (1:5000) in 2% (w/v)
milk/TBST and binding was detected using the ECL system (Amersham Phar-
macia, Freiburg, Germany). Unprocessed scans of the dot blots are provided at the
end of the Supplementary information.
To extend the screening for infectious antigens, the recombinant NLPHL-Fabs
were screened together with recombinant Fabs of different B-cell neoplasias at
concentrations of 1, 10, and 20 µg/ml on an infectious disease epitope microarray
(PEPperCHIP®/Heidelberg, Germany) consisting of 3760 database-derived B-cell
epitopes from 190 pathogens, including 113 viruses, 41 bacteria, 25 parasites, 10
worms, and 1 pathogenic fungus. Goat anti-human IgG (H+ L) conjugated to
DyLight680 (1:5000) was used as secondary antibody and incubated for 45 min at
room temperature. As a scanner the LI-COR Odyssey Imaging System was used
with a scanning offset of 0.65 mm, a resolution of 21 µm and scanning intensities of
7/7 (red= 700 nm/green= 800 nm). Data quantification was followed by removal
of spots with a deviation of more than 40%. Screening, scanning, and data analysis
was performed by PEPperPRINT GmbH in Heidelberg, Germany.
To screen Fabs against autoantigens, high-density cDNA library protein
expression macroarrays (UniPex 1 & 2, Bioscience, Dublin, Ireland) consisting of
15,300 spotted UniPEx expression clones derived from human fetal brain, T cells,
lung, and colon, which, after induction of expression, represent 7390 distinct
recombinant human proteins were used19. Protein-macroarrays were blocked in
10% (w/v) non-fat dry milk powder in TBST at 4 °C overnight, washed twice in
TBST and incubated for 1 h with pooled Fabs for the protein-arrays, each at a
concentration of 10 µg/ml. Following three 30 min TBST washes and subsequent
incubation for 1 h at room temperature with biotinylated goat anti-human Fab
antibody (DIANOVA, 109-065-088) at a dilution of 1:5000 (v/v) the arrays and
blots were incubated for 10 min at room temperature with Strep-POX (1:5000) in
2% (w/v) milk/TBST and binding was detected using the ECL system (Amersham
Pharmacia).
Antigen characterization. To characterize antigens detected in the M. catarrhalis
lysate, PAGE separations ofM. catarrhalis lysates from a clinical isolate propagated
from a patient with respiratory infection and a lysate of the strain ATCC 43617 RO
108 were performed and were Western blotted under reducing and non-reducing
conditions with M. catarrhalis-reactive LP cell-derived recombinant Fabs and
highly diluted (10−6) serum of a patient with IgD-secreting multiple myeloma. To
identify the specific M. catarrhalis antigen of 150–160 kDa detected by Western
blot out of more than 1800 known M. catarrhalis genes, an approach based on
published literature and hypothetic assumptions was chosen to select possible
candidate antigens. Literature search resulted firstly in the selection of MID/hag as
possible candidate antigen, as it had previously been proposed as an antigen
involved in the generation of IgD-only B cells, although the molecular weight is
reported to be higher than that of the identified target antigen30. Moreover, only
very few proteins of M. catarrhalis outer membrane vesicles have been reported to
have as high molecular weights as the identified antigen of 150–160 kDa16. In a
published list of the 50 most immunogenic B cell epitopes of M. catarrhalis, RpoC
was the only protein with a molecular weight around 155 kDa48. By these means
RpoC was selected as second hypothetic M. catarrhalis candidate antigen.
To characterize antigens detected in the M. osloensis lysate, the lysate was
separated in two-dimensional gels, followed by silver staining and Western blot
with M. osloensis-reactive LP cell-derived recombinant Fabs as primary antibody
(patient #11) followed by mass spectroscopy (Proteome Factory AG, Berlin,
Germany). In short, NCBIprot database version 20161128 was used
(106762850 sequences, 39119668168 residues) with the following parameters:
enzyme: trypsin; fixed modifications: carbamidomethyl (C); variable modifications:
deamidated (NQ), oxidation (M); mass values: monoisotopic; protein mass:
unrestricted; peptide mass tolerance: ±3 ppm; fragment mass tolerance: ±0.6 Da;
max missed cleavages; instrument type: ESI-Trap.
The MID/hag and RpoC gene from M. catarrhalis and SUCLG1 gene from M.
osloensis were amplified from the respective bacterial DNA. The expression clones
of human pyruvate carboxylase, RPS27a and SMCHD1 were obtained from the
manufacturer (Bioscience, Dublin, Ireland), the latter as control antigen, as
reported previously23. Genes of MID/hag and RpoC from M. catarrhalis and of
SUCLG1 fromM. osloensis were cloned (Supplementary Table 1) with a C-terminal
FLAG-tag into pSFI vector and expressed in HEK293. Nunc maxisorb ELISA plates
were coated overnight at 4 °C with murine anti-FLAG antibody (Sigma, F3165,
Munich) 1:2500 v/v. After blocking with 1.5% (w/v) gelatin in TBS and washing
steps with TBS with Triton-X, recombinant NLPHL-derived Fabs were added at
10 µg/ml or patient sera at 1:100 for 1 h at room temperature. After washing-step
with TBS-Tx biotinylated goat anti-human IgG (heavy and light chain) (Dianova)
1:2500 v/v or sheep anti-human IgG1, IgG2, IgG3, and IgG4 (Binding Site, AU006,
AU007, AU008, and AU009, Birmingham, UK) 1:5000 (v/v) or rabbit anti-human
IgM (Dianova, 109-476-129) 1:2500 v/v were added for 1 h at room temperature
followed by washing step with TBS. For the determination of IgG subclasses and
IgM biotinylated correspondent secondary antibodies were applied. This was
followed by peroxidase-labeled streptavidin (Roche) 1:50,000.
To verify specific reactivity of IgD+, NLPHL derived Fabs againstM. catarrhalis
RpoC, recombinant Fabs derived from 11 cases of PCNSL, 12 cases of DLBCL, 10
cases of MCL, and 12 cases of CLL were screened against M. catarrhalis lysates on
dot blots and against recombinant FLAG-tagged M. catarrhalis RpoC by
ELISA22,23,49.
Generation of DEV cells expressing recombinant BCRs. The only existing
NLPHL cell line (DEV) was cultured at 37 °C in an atmosphere containing 5% CO2
in RPMI-1640 medium supplemented with penicillin (100 U/ml), streptomycin
(0.1 mg/ml), ultraglutamine (2 mM), and 20% fetal calf serum, and transfected with
a pRTS expression vector with an IgV region heavy chain and constant regions
Cγ1–Cγ4, Cµ1–Cµ4, or Cδ1–Cδ4 with membrane coding exons TM1 and TM2 for
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the transmembrane region and the cytoplasmic tail followed by a 2A sequence and
the light chain variable region and light chain constant region gene. Transfection of
DEV cells was performed after three washing steps with RPMI-1640 at a cell
density of 2 × 107/ml in RPMI-1640 without FCS on ice. Two times 106 cells
equalizing a volume of 100 µl were transfected with 5 µg plasmid DNA by elec-
troporation using Gene Pulser (Biorad) with a 0.2 cm cuvette, a voltage of 140 V
and 30 ms pulses. Subsequently cells were immediately put again on ice and
cultured in RPMI-1640 medium supplemented with 20% FCS (Sigma, F2442). Cell
lines stably expressing recombinant membranous BCR were selected with hygro-
mycin at 250 µg/ml. Expression of recombinant BCR was induced by addition of
doxycycline50. Successful transfection was verified by IgV region gene PCRs of
transfected cell lines, by Western blot of the FLAG-tagged recombinant BCRs and
surface expression of the transfected His-tagged BCR was determined by flow
cytometry. In detail, surface expression of recombinant patient-derived BCRs on
the membrane of DEV cell line was verified by flow cytometry using the BD FACS
Canto and either the original DEV cell line or DEV cell lines transfected to express
LP cell-derived BCR, which contain His6 tags. Cells were incubated with murine
Anti-His antibody (Qiagen, 34660, Hilden, Germany) (1:500) followed by bioti-
nylated anti-murine antibody (1:200) and PE-labeled streptavidin (Qiagen, 016-
110-084) (1:500) each for 20 min at 4 °C with washing steps in between (Supple-
mentary Fig. 15).
BCR and NF-κB pathway activation and proliferation assay. For Western blot
analysis of the BCR pathway activation of transfected DEV cells either expressing a
BCR with reactivity against M. catarrhalis RpoC or a different antigen, respectively,
and of IgD, IgG, or IgM class, 1 × 106 cells were incubated with no antigen,
recombinant RpoC at 5 µg/ml, RpoC and MID/hag fragment 2&3, MAZ at 5 µg/ml
or anti-IgM/IgD at 1 µg/ml. As primary antibodies rabbit antibodies against
pTyr525/526 SYK diluted 1:2000, pTyr759 PLCγ2 diluted 1:1000, pTyr223 BTK
diluted 1:1000, and pTyr96 BLNK diluted 1:1000 (B cell signaling sampler kit,
9768, CST, Massachusetts, USA), rabbit antibody against actin diluted 1:2000
(Sigma, A5060), and murine antibody against MYC at a concentration of 1 µg/ml
(Santa Cruz) were utilized, followed by washing steps and incubation with POX-
conjugated anti-rabbit or anti-mouse antibodies diluted at 1:3000. For analysis of
the NF-κB pathway mouse antibody against IKKα and IκBα, rabbit antibodies
against IKK, pSer176/180 IKKα/β, pSer536 NF-κB p65, NF-κB p65, and against
pSer32 IκBα were used (NF-κB pathway sampler kit, 9936, CST,
Massachusetts, USA).
For the analysis of cytoplasmatic calcium changes by flow cytometry a FACS
Canto analyzer was used and Fluo-4/AM dye (Molecular probes, Invitrogen,
F14201). Transfected DEV cells either expressing IgD+ BCRs with reactivity
against RpoC or against a different antigen were resuspended in calcium-free and
magnesium-free phosphate-buffered saline, and loaded with Fluo-4/AM dye (final
concentration 2 μM, Invitrogen, Karlsruhe, Germany) for 30 min at room
temperature. Antigen was added followed by flow cytometry of the cells.
Ionomycin (10 ng/μl, Sigma-Aldrich, 407952) was used as a positive control for the
release of calcium from internal stores. Intracellular calcium levels were repeatedly
analyzed immediately after adding the antigen to the dye-loaded cells and mixing.
To exclude cell debris DEV cell line was gated for relatively high FSC and low SSC.
EZ4U, a non-radioactive proliferation assay (Biomedica, BI-5000), was
performed according to the manufacturer’s instructions with DEV cells (IgD−),
and the DEV cell line transfected to express RpoC-reactive surface BCR of the IgD
class, and as further control a DEV cell line expressing RpoC-reactive membranous
IgG BCR. The IgV genes were derived from case 3, and the IgD constant region
gene from PBMCs of a healthy blood donor51,52. M. catarrhalis RpoC and as a
control recombinant human SLP2, which is a frequent antigenic target of
paraproteins from patients with multiple myeloma, were added at 10 µg/ml.
Recombinant fragments of M. catarrhalis MID/hag spanning amino acids 1–761
(fragment 1), amino acids 920–1368 (fragment 2), and amino acids 920–2090
(fragment 3) were added to DEV cell cultures at 5 µg/ml. Adsorbance of Formazan
at 450 nm was determined after 3 days at 37 °C. Statistical significance was
calculated by multiple t-tests (Prism7, graphpad).
Cytotoxicity and apoptosis assays. For the analysis of the direct cytotoxic effects
of immunotoxins a lactate dehydrogenase (LDH) release assay was used (Roche,
04744926001). 5 × 103 DEV cells per well, stably transfected to express the BCR of
case #3 with reactivity against M. catarrhalis RpoC or of case #5 without reactivity
against M. catarrhalis RpoC were incubated with RpoC/ETA or Ars2/ETA at
concentrations from 0.1 to 10 µg/ml, or without an immunotoxin. Percent-specific
lysis was determined after 24 h at 37 °C as follows: (experimental lysis−sponta-
neous lysis)/(maximum lysis–spontaneous lysis) × 100. Maximum lysis was deter-
mined by adding 10% Triton X-100. LDH was measured according to the protocol
of the LDH assay kit (Roche, Mannheim, Germany). ELISA read out was done
using a Victor II apparatus (PerkinElmer, Rodgau, Germany). For the analysis of
apoptosis, 5 × 105 cells/ml suspension of DEV cells stably transfected to express
either a BCR with reactivity against RpoC or a different antigen were treated by
adding RpoC/ETA, MAZ/ETA (both at 0.5 µg/ml) or RpoC/ETA and MID/hag for
24 h at 37 °C, 5% CO2. Following the incubation, cells were washed twice with PBS
and resuspended in 500 µl binding buffer. 5 µl of AnnexinV-FITC (SIGMA,
APOAF) and 10 µl of propidium iodide (SIGMA) were added to each cell
suspension and incubated for 10 min at room temperature, followed by analysis by
FACS Canto. In addition, the effects of the immunotoxins were measured by
trypan blue assays at 0, 24, and 48 h.
HLA typing. HLA-typing of class I and II human leukocyte antigens (HLA) was
performed for all patients with IgD+ LP cells by sequence-based typing (Labor
Thiele, Kaiserslautern, Germany).
Analysis of binding and internalization. To analyze binding to and internaliza-
tion of RpoC into DEV cells transfected to express RpoC-reactive BCRs, a synthetic
RpoC peptide consisting of the amino acid sequence VAAKDVVNADGDVV
VPSGALIDERL with a C-terminal FITC (purity > 95%, Genecust, Luxembourg)
was added at a concentration of 10 µg/ml or as a control CD30/FITC to DEV lines
transfected either with RpoC-reactive BCR (derived from case #6) or without
RpoC-reactive BCRs (derived from case #5) for 30 min at 4 °C. Cells were then
immediately, or after 1 h incubation at 37 °C analyzed. To determine surface
binding or internalization of RpoC/FITC half of the cells were washed and analyzed
directly by flow, and the other half of cells was washed, treated by azide 2% for 5
min to solve the surface-bound antigen, washed again followed by flow cytometry.
Data availability
All relevant data are available in the Article, Supplementary Information or from the
corresponding author upon reasonable request.
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